RLYP - down to upper $14s afterhours on news of $150M financing via debt. Nondilutive, i presume, but having to pay 11%, though with a few years of interest-only payments. Market doesn't like it but this solves their cash problem for the year and into next year.... Competitor drug ZS-9 may get problematic or bad news from FDA this May either with black-box warning label (e.g., re: sodium levels) or even non-approval, which would skyrocket RLYP but i only give the chances of that non-approval happening to be about 15% (jmo). I'm about 80% sure that ZS-9 will get a warning label.
Also, there is always the good chance there will be another leaked blurb on "buyout talks happening" if not actual buyout news at some point.
I'm thinking of getting back into this one if it goes down to low $14s or $13s.....
